Author:
Kanavos Panos G.,Vandoros Sotiris
Abstract
AbstractThis paper investigates the determinants of the prices of branded prescription medicines across different regulatory settings and health care systems, taking into account their launch date, patent status, market dynamics and the regulatory context in which they diffuse. By using volume-weighted price indices, this paper analyzes price levels for a basket of prescription medicines and their differences in 15 OECD countries, including the United States and key European countries, the impact of distribution margins and generic entry on public prices and to what extent innovation, by means of introducing newer classes of medicines, contributes to price formation across countries. In doing so, the paper seeks to understand the factors that contribute to the existing differences in prices across countries, whether at an ex-factory or a retail level. The evidence shows that retail prices for branded prescription medicines in the United States are higher than those in key European and other OECD countries, but not as high as widely thought. Large differences in prices are mainly observed at an ex-factory level, but these are not the prices that consumers and payers pay. Cross-country differences in retail prices are actually not as high as expected and, when controlling for exchange rates, these differences can be even smaller. Product age has a significant effect on prices in all settings after having controlled for other factors. Price convergence is observed across countries for newer prescription medicines compared with older medicines. There is no evidence that originator brand prices fall after generic entry in the United States, a phenomenon known as the ‘generics paradox’. Finally, distribution and taxes are important determinants of retail prices in several of the study countries. To the extent that remuneration of the distribution chain and taxation are directly and proportionately linked to product prices this is likely to persist over time.
Publisher
Cambridge University Press (CUP)
Reference53 articles.
1. World Health Organization ATC/DDD Index (2008), http://www.whocc.no/atcddd [November 2008].
2. Sorenson C. , Drummond M. , Kanavos P. (2008), ‘Ensuring Value for Money in Health Care: The Role of HTA in the European Union’, Financing Sustainable Healthcare in Europe: New Approaches for New Outcomes, European Observatory on Health Systems and Policies, Buckingham: Open University Press.
3. Prices for Innovative Pharmaceutical Products That Provide Health Gain: A Comparison Between Australia and the United States
4. Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献